Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Earnings Results

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03), Zacks reports. Alnylam Pharmaceuticals updated its FY 2025 guidance to EPS.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded down $8.44 during trading hours on Monday, reaching $256.45. The company had a trading volume of 805,993 shares, compared to its average volume of 695,622. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39. The business has a fifty day simple moving average of $254.03 and a 200 day simple moving average of $263.53. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market cap of $33.08 billion, a PE ratio of -97.88 and a beta of 0.35.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ALNY shares. Royal Bank of Canada restated an "outperform" rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 11th. Piper Sandler restated an "overweight" rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an "equal weight" rating in a research report on Friday. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Finally, TD Cowen upped their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $299.43.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 73,964 shares of company stock valued at $20,622,925 over the last three months. Company insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.